It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Completely Resected EGFR Mutant Non-Small Cell Lung Cancer Treatment Study

Clinical Trial Title: 
Randomized double blind placebo controlled study of erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC).
Clinical Trial Protocol ID: 
16020504
Clinical Trial Investigator Name: 
Marta Batus, MD
Clinical Trial Protocol Description: 

The purpose of this study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug). Treatment in both groups will last for up to 2 years, as long as you do not have too many side effects and the tumor has not grown back. While you are receiving treatment you will see your doctor for a check up and certain tests every 3 weeks for the first 12 weeks after you start treatment, and then at least every 6 weeks while you continue on treatment. You will have an equal chance of being placed in either group.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have previously registered to A151216, with the result of lung cancer harboring an EGFR exon 19 deletion or L858R mutation.
  • Have completely resected stage IB (>= 4 cm), II or IIIA non-squamous NSCLC with negative margins.
  • Have complete recovery from surgery and standard post-operative therapy (if required).

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Lung and Chest Tumors
Contact Phone: 
(312) 563-3921
Contact Name: 
Emily Rubenstein, RN